Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
Launched by PFIZER · Nov 28, 2022
Trial Information
Current as of January 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two medicines, Aztreonam and Avibactam, to see how they work and how safe they are for children with serious bacterial infections caused by gram-negative bacteria. The trial is open to children aged 9 months to less than 18 years who are currently in the hospital and need intravenous (IV) antibiotics for complicated infections in areas like the abdomen, urinary tract, bloodstream, or lungs. If eligible, participants will receive either the new medicine combination (ATM-AVI) or the best available treatment.
During the study, participants will have some blood tests and may switch to oral medications after a few days, depending on their response to treatment. The total duration of the study for each participant will be between 33 to 50 days, including any follow-up calls to check on their health after treatment. It's important to know that certain conditions may exclude children from participating, such as specific infections that do not respond well to the medicines being tested or certain medical issues. The trial aims to provide valuable information about treating serious infections in children and is currently recruiting participants.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:
- • 1. Participants ≥9 months to \<18 years of age at Screening; Female (post-menarchal) participants must have a negative serum/urine pregnancy test (β hCG sensitivity ≥25 mIU/mL).
- • 2. Suspected/confirmed cIAI, cUTI, HAP/VAP, or BSI with gram-negative pathogens.
- • 3. Require hospitalization and IV antibiotic treatment.
- • Exclusion Criteria
- Participants with any of the following characteristics/conditions will be excluded:
- • 1. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- • 2. Gram-negative species not expected to respond to ATM AVI ≤14 days.
- • 3. Pregnant or breastfeeding; fertile male/female unwilling/unable to use effective contraception for at ≥7 days (males) or ≥28 days (females) after last ATM-AVI infusion.
- (HAP/VAP only):
- • 4. Microbiologically known or high likelihood of monomicrobial infection with a gram-positive organism, lung abscess, pleural empyema, or post-obstructive pneumonia, lung or heart transplant.
- • 5. Received \>24 hours of systemic antibiotics during the 48 hours before randomization unless participant has documented treatment failure after at least 48 hours of antibiotic therapy.
- • 6. Current use of any prohibited concomitant medication(s) or unwilling/unable (Cockayne Syndrome patients with cIAI are excluded) to use MTZ or having received previous investigational drug(s) or vaccine ≤30 days or 5 half-lives before randomization (whichever is longer).
- • 7. CrCL ≤15 mL/min/1.73 m2 (eCrCl or eGFR calculation based on age).
- • 8. Non-infectious related screening ALT or AST \>3 x ULN, ALP \>3 x ULN and/or TBili \>2 x ULN (\> 3 x ULN for Gilbert's syndrome).
- • 9. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
New York, New York, United States
Madrid, , Spain
Taipei, , Taiwan
Taipei, , Taiwan
San Diego, California, United States
Taipei, , Taiwan
Barcelona, , Spain
New York, New York, United States
Kolkata, West Bengal, India
Taoyuan, , Taiwan
Budapest, , Hungary
Budapest, , Hungary
Memphis, Tennessee, United States
Budapest, , Hungary
Surat, Gujarat, India
Boadilla Del Monte, Madrid, Spain
Shanghai, Shanghai, China
Beijing, Beijing, China
New York, New York, United States
Esplugues De Llobregat, Barcelona [Barcelona], Spain
Badalona, Barcelona [Barcelona], Spain
Bengaluru, Karnataka, India
Madrid, Madrid, Comunidad De, Spain
Istanbul, İ̇stanbul, Turkey
Heraklion, Irakleío, Greece
İzmir, İ̇zmir, Turkey
Kolin 3, Kolín, Czechia
Thessaloniki, Kentrikí Makedonía, Greece
Baja, Bács Kiskun, Hungary
Adana, , Turkey
Most, , Czechia
Bangalore, Karnataka, India
Guangzhou, Guangdong, China
New York, New York, United States
Sarçam, Adana, Turkey
Chengdu, Sichuan, China
Chengdu, Sichuan, China
Hsinchu City, Hsinchu, Taiwan
Chongqing, Chongqing, China
Pune, Maharashtra, India
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials